Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed a non-disclosure agreement (“NDA”) with an internationally known drug delivery device manufacturer. The NDA permits PreveCeutical to have discussions with the manufacturer regarding the supply of spray devices for use in the company’s soluble gel (“Sol‑gel”) drug delivery research program. The company’s research partner, the University of Queensland, has received various prototype spray devices from the manufacturer at the Pharmacy Australia Centre of Excellence, where testing of the devices for the program is taking place. “We are pleased to have signed an NDA with this world-leading manufacturer that has set a standard for the drug delivery industry with their advanced quality products. Their recognition of the significance of safety regulations, such as tamper-proof drug delivery devices, are of the upmost importance to us. Although the Program is still in its preliminary stage, coordinating the evaluation of drug delivery devices in parallel with the Sol-gel Program demonstrates PreveCeutical’s commitment to bringing the Sol-gel nose-to-brain delivery system to market,” PreveCeutical Chairman, CEO and President Stephen Van Deventer stated in the news release.
To view the full press release, visit http://nnw.fm/Ta8em
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com